2026-02-18——
Merck and Mayo Clinic announce R&D collaboration for AI-enabled drug discovery and precision medicine
A short entry: a summary of the public record, checked against its sources, not yet read and analysed by Gianluca. How the register works
On 18 February 2026, Merck and Mayo Clinic announced a research and development agreement giving Merck access to Mayo Clinic Platform, including de-identified clinical, genomic and multimodal data, to support AI-enabled drug discovery. Initial focus is on inflammatory bowel disease, atopic dermatitis and multiple sclerosis.
What happened
- Announced 18 February 2026 by Merck (NYSE: MRK) and Mayo Clinic.
- The agreement marks Mayo Clinic's first strategic collaboration of this scale with a global biopharmaceutical company.
- Merck accesses Mayo Clinic Platform_Orchestrate, providing de-identified clinical and multimodal data sets, registries and biorepositories, plus AI tools and analytics, drawing on Mayo Clinic U.S. and its international partner network.
- Multimodal data covered includes laboratory results, medical imaging, clinical notes and molecular data.
- Initial therapeutic focus: inflammatory bowel disease (gastroenterology), atopic dermatitis (dermatology) and multiple sclerosis (neurology).
- Merck reported 2025 revenue of US$65.01 billion; Keytruda generated $29.5 billion in 2024, representing 46% of company revenue.
Sources
- merck.com — primary
- en.wikipedia.org — party background
- postbulletin.com — party background
- en.wikipedia.org — party background
Announced 2026-02-18 · Added to the register 2026-09-30